aTyr Reports ATYR2810 Preclinical Osteosarcoma Data at CTOS 2026 Meeting

aTyr Reports ATYR2810 Preclinical Osteosarcoma Data at CTOS 2026 Meeting
aTyr Reports ATYR2810 Preclinical Osteosarcoma Data at CTOS 2026 Meeting

aTyr presents preclinical data on osteosarcoma treatment candidate

November, 20 2026
Click to view quick news summary (Spoiler)

aTyr reported that its investigational NRP2 antibody ATYR2810 reduced osteosarcoma growth and lung metastases in preclinical mouse models.

SAN DIEGO - aTyr Pharma Inc. presented preclinical data for ATYR2810, a monoclonal antibody targeting neuropilin-2, at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting held November 18-21 in Seoul, South Korea, according to a press release statement.

The preclinical studies showed ATYR2810 inhibited tumor growth and metastasis of osteosarcoma to the lungs in mouse models, including human patient-derived orthotopic models and a syngeneic mouse model. The treatment showed effects on tumor recurrence after drug removal at day 25, with effects lasting to 45 days. A reduction in lung metastases was observed in the studies.

The research evaluated ATYR2810 in osteosarcoma models using spatial transcriptomics and in vivo testing. Treatment in mice was associated with reduced tumor growth and metastasis without evidence of overt toxicity. NRP2 was expressed on malignant osteosarcoma cells and macrophages.

Osteosarcoma is the most common type of primary malignant bone cancer in children and adolescents, with approximately 1,000 new cases diagnosed annually in the United States. The disease can spread to other organs, most commonly the lungs. Current standard of care includes chemotherapy and surgery. Approximately 40% of those treated experience a relapse or recurrence.

ATYR2810 is a fully humanized monoclonal antibody designed to block the neuropilin-2 receptor. NRP2 is a cell surface receptor expressed in many tumors and is associated with cancer progression, drug resistance development and metastatic spread. The antibody is in preclinical development for aggressive cancers where NRP2 is implicated and has completed GLP toxicology testing in non-human primates and cGMP manufacturing.

aTyr is a clinical stage biotechnology company focused on developing therapies from its tRNA synthetase platform. The company’s lead therapeutic candidate is efzofitimod, in clinical development for interstitial lung disease.

0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company

We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.

Accept